# PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

> **NCT02039817** · PHASE1 · COMPLETED · sponsor: **Conatus Pharmaceuticals Inc.** · enrollment: 16 (actual)

## Conditions studied

- Renal Impairment
- Renal Insufficiency
- Kidney Disease
- Kidney Diseases

## Interventions

- **DRUG:** IDN-6556

## Key facts

- **NCT ID:** NCT02039817
- **Lead sponsor:** Conatus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2016-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02039817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02039817, "PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02039817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*